Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7562572 | 0.79 | PTPRC (0.35) | KMT2AMAPTKDM4EALDH1A1PTPRC | |
| SCHEMBL7832092 | 0.76 | ITGA4 (0.41) | KMT2AMAPTMEN1OPRM1OPRD1 | |
| SCHEMBL6782285 | 0.73 | IRAK4 (0.39) | KMT2AGRM5MEN1OPRM1OPRD1 | |
| SCHEMBL7117442 | 0.69 | ELANE (0.44) | KMT2AMAPTHTTKDM4EALDH1A1 | |
| SCHEMBL15244893 | 0.69 | SCN9A (0.41) | KMT2AMEN1HTTALDH1A1PKM | |
| SCHEMBL5849169 | 0.68 | EPHX2 (0.50) | KMT2AMAPTMEN1HTTKDM4E | |
| SCHEMBL7345217 | 0.68 | TSHR (0.36) | KMT2AMAPTMEN1HTTKDM4E | |
| SCHEMBL16766069 | 0.68 | XIAP (0.35) | KMT2AMAPTKDM4EALDH1A1PTPRC | |
| SCHEMBL6936747 | 0.68 | MEN1 (0.41) | KMT2AMEN1CTSAALDH1A1PTPRC | |
| SCHEMBL16680856 | 0.67 | ALDH1A1 (0.44) | MAPTALDH1A1PTPRCL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |